Ser266
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.8.0
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser266  -  UBE2J1 (human)

Site Information
QQSQRRLstsPDVIQ   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2158876

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 16 , 17 , 18 , 19 , 20 , 21 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 )
Disease tissue studied:
breast cancer ( 7 , 8 , 18 , 19 ) , breast ductal carcinoma ( 7 ) , HER2 positive breast cancer ( 3 ) , luminal A breast cancer ( 3 ) , luminal B breast cancer ( 3 ) , breast cancer, surrounding tissue ( 3 ) , breast cancer, triple negative ( 3 , 7 ) , cervical cancer ( 32 ) , cervical adenocarcinoma ( 32 ) , leukemia ( 20 ) , acute myelogenous leukemia ( 20 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 17 , 20 ) , acute megakaryoblastic leukemia (M7) ( 17 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 17 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 17 ) , acute myeloblastic leukemia, without maturation (M1) ( 17 ) , hepatocellular carcinoma, surrounding tissue ( 30 ) , lung cancer ( 6 , 12 , 19 , 27 , 34 ) , non-small cell lung cancer ( 19 , 34 ) , non-small cell lung adenocarcinoma ( 6 , 12 ) , B cell lymphoma ( 17 ) , non-Hodgkin's lymphoma ( 17 ) , ovarian cancer ( 7 ) , pancreatic ductal adenocarcinoma ( 11 ) , multiple myeloma ( 17 ) , melanoma skin cancer ( 5 )
Relevant cell line - cell type - tissue:
'pancreatic, ductal'-pancreas ( 11 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 28 ) , 293E (epithelial) ( 24 ) , A498 (renal) ( 29 ) , A549 (pulmonary) [CD38 (human), transfection, Lentiviral particles containing CD38 vector were transfected] ( 1 ) , A549 (pulmonary) ( 1 , 13 ) , AML-193 (monocyte) ( 17 , 20 ) , breast ( 3 , 7 ) , BT-549 (breast cell) ( 19 ) , Calu 6 (pulmonary) ( 19 ) , CL1-0 (pulmonary) ( 27 ) , CL1-1 (pulmonary) ( 27 ) , CL1-2 (pulmonary) ( 27 ) , CL1-5 (pulmonary) ( 27 ) , CMK (megakaryoblast) ( 17 ) , CTS (myeloid) ( 17 ) , DOHH2 ('B lymphocyte, precursor') ( 17 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 21 ) , Flp-In T-Rex-293 (epithelial) ( 21 ) , H2009 (pulmonary) ( 19 ) , H2077 (pulmonary) ( 19 ) , H2887 (pulmonary) ( 19 ) , H322M (pulmonary) ( 19 ) , HCC1937 (breast cell) ( 19 ) , HCC2279 (pulmonary) ( 19 ) , HCC366 (pulmonary) ( 19 ) , HCC78 (pulmonary) ( 19 ) , HEL (erythroid) ( 17 , 20 ) , HeLa (cervical) ( 2 , 16 , 26 , 33 , 37 , 39 ) , HeLa S3 (cervical) ( 32 ) , hepatocyte-liver ( 30 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 8 ) , HMLER ('stem, breast cancer') ( 8 ) , HOP62 (pulmonary) ( 19 ) , HUES-9 ('stem, embryonic') ( 25 ) , Jurkat (T lymphocyte) ( 14 , 35 , 36 ) , K562 (erythroid) ( 16 , 33 ) , Kasumi-1 (myeloid) ( 17 ) , KG-1 (myeloid) ( 17 ) , leukocyte-blood ( 31 ) , liver ( 10 ) , LOU-NH91 (squamous) ( 19 ) , lung ( 12 , 34 ) , MCF-7 (breast cell) ( 19 ) , MDA-MB-231 (breast cell) ( 19 ) , MV4-11 (macrophage) ( 17 , 20 ) , NCI-H1395 (pulmonary) ( 19 ) , NCI-H157 (pulmonary) ( 19 ) , NCI-H1648 (pulmonary) ( 19 ) , NCI-H1666 (pulmonary) ( 19 ) , NCI-H2030 (pulmonary) ( 19 ) , NCI-H2172 (pulmonary) ( 19 ) , NCI-H322 (pulmonary) ( 19 ) , NCI-H460 (pulmonary) ( 19 ) , NCI-H520 (squamous) ( 19 ) , OPM-2 (plasma cell) ( 17 ) , ovary ( 7 ) , P31/FUJ (erythroid) ( 17 ) , PC9 (pulmonary) ( 6 , 19 ) , RL ('B lymphocyte, precursor') ( 17 ) , RPMI-8266 (plasma cell) ( 17 ) , SH-SY5Y (neural crest) [LRRK2 (human), transfection, over-expression of LRRK2(G2019S)] ( 9 ) , SKBr3 (breast cell) ( 18 ) , SU-DHL-6 (B lymphocyte) ( 17 ) , TERT20 ('stem, mesenchymal') ( 38 ) , U266 (plasma cell) ( 17 ) , WM239A (melanocyte) ( 5 )

Upstream Regulation
Regulatory protein:
CD38 (human) ( 1 )
Treatments:
EGF ( 33 ) , ischemia ( 7 ) , metastatic potential ( 27 ) , nocodazole ( 32 ) , SB202190 ( 33 ) , U0126 ( 33 )

References 

1

Wang W, et al. (2018) Decreased NAD Activates STAT3 and Integrin Pathways to Drive Epithelial-Mesenchymal Transition. Mol Cell Proteomics
29980616   Curated Info

2

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

3

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

4

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

5

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

6

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

7

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

8

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

9

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

10

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

11

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

12

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

13

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

14

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

15

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

16

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

17

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

18

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

19

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

20

Alcolea MP, et al. (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics 11, 453-66
22547687   Curated Info

21

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

22

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

23

Rikova K (2012) CST Curation Set: 14275; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

24

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

25

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

26

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

27

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

28

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

29

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

30

Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9
20166139   Curated Info

31

Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32
20058876   Curated Info

32

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

33

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

34

Rikova K (2009) CST Curation Set: 7980; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

35

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

36

Possemato A (2008) CST Curation Set: 5691; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

37

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

38

Thingholm TE, et al. (2008) TiO2-Based Phosphoproteomic Analysis of the Plasma Membrane and the Effects of Phosphatase Inhibitor Treatment. J Proteome Res 7, 3304-3313
18578522   Curated Info

39

Yu LR, et al. (2007) Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra. J Proteome Res 6, 4150-62
17924679   Curated Info